61results about How to "Improvement in administration" patented technology

A system, software, and methods related to enhanced pharmaceutical order entry and administration by medical personnel, and enhanced pharmaceutical inventory control within a medical institution are provided. An embodiment of the system includes a pharmaceutical information management server having memory and a medication administration program product including a set of instructions stored in the memory of the pharmaceutical information management server to enhance provision of pharmacy services. The system also includes medical institution physician computers to provide for computerized physician medication order entry, pharmacy computers to provide for review and verification by a pharmacist of electronic medication orders placed through the physician computers, and medical institution nursing unit computers, to provide for review of and input to electronic medication administration records.

The present invention provides combination therapies for treating a disease, disorder, or condition, and methods thereof.

Fentanyl-containing dosage forms and methods using same are described. These dosage forms include substantially less fentanyl by weight than known oral formulation and have advantages in terms of reduced cost and reduced side effects. These dosage forms are intended for oral administration of fentanyl across the oral mucosa.

The present invention concerns compounds comprising, within short sequences from a specific region of the kinase, that can modulate kinase-associated signal transduction.

The invention provides a medical device having a thermister for temperature measurement, irrigation / aspiration ports for fluid exchange and application of therapeutic modalities, a pressure manometer for pressure measurement, and an external system for control of temperature, pressure, and flow rate. When applied to the eye, eyelid and orbit, this device can be used in hypothermia or hyperthermia applications, the control of intraocular pressure (IOP), and the application of treatment modalities. Methods of using the device in treating patients suffering from central retinal artery occlusion, anterior optic nerve disease, pathology of the choroid and retina including the macula, inflammation of the eye including the vitreous and anterior segment, glaucoma, inflammation and / or infections of the anterior and / or posterior segment of the eye, treatment before / during / after surgery of the eye, and the application of treatment modalities including iontophoresis through a semi-permeable membrane are described.

Transdermal delivery peptides for the treatment of skin diseases and / or facilitation or enhancement of transdermal delivery of pharmaceutically active agents are provided. Compositions comprising the transdermal delivery peptides and methods of therapeutic use, including the improvement of transdermal delivery of drugs or other pharmaceutically active agents, are also disclosed. Nucleic acids, expression vectors, and methods of their use, which encode the transdermal delivery peptides are disclosed. Methods are also provided for in vivo phage display for identifying further peptides with enhanced transdermal delivery capability.

A method of measuring Reelin as a biomarker, to non-destructively assess or predict DHA levels in the brain and in other, currently inaccessible or difficult-to-access, key components of the central nervous system (CNS) is described. Also described is a method to prevent, delay the onset of, or treat Reelin deficiency or dysfunction and / or a disease or condition associated with Reelin deficiency or dysfunction, comprising administering to a patient diagnosed with or suspected of having a Reelin deficiency or dysfunction an amount of a PUFA, and particularly an omega-3 PUFA, and more particularly, docosahexaenoic acid (DHA) or a precursor or source thereof, to compensate for the effects of Reelin deficiency or dysfunction in the patient. Also described is a method to prevent or reduce developmental defects or disorders associated with Reelin dysfunction or deficiency through the supplemental use of polyunsaturated fatty acids (PUFAs—unsaturated fatty acids having two or more double bonds), and particularly highly unsaturated fatty acids (HUFAs—unsaturated fatty acids having three or more double bonds), and more particularly a HUFA selected from arachidonic acid (ARA), eicosapentacnoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA), and even more particularly omega-3 HUFAs, and more particularly DHA, to: compensate for reduced fatty acid binding protein or function thereof in the patient; compensate for reduced brain lipid binding protein or function thereof in the patient; improve the activity of fatty acid binding proteins in the patient; increase the expression of brain lipid binding proteins (BLBPs) in the patient; improve at least one parameter of the mechanism of action of brain lipid binding proteins in the patient; overcome a deficiency of DHA in central nervous system (CNS) structures and improve the resulting function thereof; increase the incorporation of functional DHA and other PUFAs into the phospholipid membranes of glial cells and neurons in the patient; increase the level of Reelin and / or improve the activity of Reelin in the patient; and / or improve at least one symptom of a disease or condition associated with Reelin deficiency or dysfunction.

An enteral administration assembly for administering fluids through an enteral device. The administration assembly comprising an inlet, an outlet, and a valve mechanism between the inlet and outlet. The inlet is configured to interlock with only an enteral device to form a sealed connection allowing the passage of fluid between the enteral device and the inlet. The assembly may include a valve or turbulating mechanism comprising a valve and at least one turbulator adapted to change the direction of fluid flowing through the assembly to prevent clogging and flocculation of administered substances.

The present invention provides methods and compositions for modulating polyamine pathway activity as a means for ameliorating neurodegenarative disorders. In particular, for ameliorating the symptoms or onset of amyotrophic lateral sclerosis (ALS) by modulating the gene and protein products involved the polyamine pathway, such as by inhibiting the enzyme, ornithine decarboxylase (ODC), involved in the synthesis of the polyamine, putrescine. Compositions and methods are disclosed for inhibiting the polyamine pathway producing lower polyamine levels resulting in a beneficial effect on ALS. This can be accomplished by using modulating agents such as analogs, or polyamine analogs, and antiproliferative drugs. In particular, the polyamine analog N(1),N(11)-diethylnorspermine (DENSPM) is disclosed as a useful modulating agent in the treatment of ALS. Screening assays for pharmacological agents that are capable of decreasing polyamine levels and / or reducing cell proliferation are also disclosed.

An iontophoresis device for administering drug ions via the first ion-exchange membrane, comprising a first semi-permeable film having a number of pores passing through the film from a front surface to a back surface, a first ion-exchange membrane formed of ion-exchange resin filling the pores of the first semi-permeable film and selective ions of a first polarity, and a working electrode structure having a drug holding part placed on a back surface of the first ion-exchange membrane and holding a drug solution containing drug ions charged in the first polarity, wherein a layer of a water-soluble polymer compound chemically bonded on the surface of the first semi-permeable film.

To overcome shortcomings of the prior art, the subject invention is provided which includes various dropper bottle designs and dropper bottle assemblies including accessories for dropper bottles. With certain aspects of the subject invention, improvements in the administration of eye drops is provided by adding accessories or modifications to conventional dropper bottles, so that doses and / or single drops may be administered in a repeatable and reliable manner. More specifically, certain embodiments use devices (10, 300) to restrict the amount the dropper bottle (12) is deformed in administering a dose; other embodiments rely on mechanical reduction of interior volume (without deformation of the dropper bottle (12)) to administer a dose, such as with a displaceable piston (500, 602); and, yet, a further embodiment provides a valving arrangement (402, 404) to limit a dose. Features (200) are also included which aid in the alignment of the dropper bottle's nozzle to the eye, and a feature (102) is provided for protecting the user's eye from potential damage which can occur if a pointed nozzle (104) is brought into contact with the eye during alignment. As will be appreciated by those skilled in the art, the various aspects and embodiments disclosed herein may be used singularly or in various combinations.

The present invention concerns methods for the treatment of prostate cancer by the inhibition of Lyn-kinase associated signal transduction. Preferred in accordance with the invention are inhibitors which comprise sequences derived from specific regions of the Lyn-kinase.

A method for improving intracellular administration of a therapeutic agent is provided comprising: contacting cells with a compound comprising a charged derivative of a therapeutic agent having a therapeutic activity, the charged derivative being conjugated to a protein having a biological activity of being transported across a cell membrane into a cell; and having the cell transport the compound into the cell where the cell metabolizes at least a portion of the compound to form a charged metabolite product that possesses the therapeutic activity of the therapeutic agent, the charged metabolite product being less prone to being transported across the cell membrane out of the cell relative to the compound and less prone to being transported across the cell membrane out of the cell relative to the therapeutic agent.

The present invention relates to a position determination device (100) (and system) for determining and registering an injection location of a liquid drug administered on a body part of a user, wherein the position determination device (100) (and system) comprises a position determination element (110) configured to provide a position signal representing a current location of the position determination device (100), and one or more processing units (150) configured to derive data representing an actual injection location based on the user in response to a current location being determined by the position determination unit (110).

A compressed chewing gum tablet includes at least a first and a second chewing gum module, the first chewing gum module including a first chewing gum composition including at least a first active ingredient and chewing gum granules containing gum base, the second chewing gum module including a second chewing gum composition including at least a second active ingredient and chewing gum granules containing gum base, wherein the first active ingredient is a pharmaceutically active ingredient, and the second active ingredient is selected from the group consisting of pharmaceutically active ingredients and enhancers, wherein the gum base content of the first and second chewing gum modules is different.

In a method for administering radio resources in a mobile radio cell, which includes a plurality of mobile terminals which are distinguishable by their radio signals, and a base station, the administration of radio resources of a mobile radio cell is improved to such an extent that the available radio resources are utilized more economically. A mobile terminal is requested by the base station to send out a signal, currently present at a receiver of the mobile terminal, which is representative of an interference situation at the location of the mobile terminal. This is sent together with information for estimating the channel between the mobile terminal and the base station so that the base station receives raw data at the location of the mobile terminal, and evaluates the signal received from the mobile terminal and the information for estimating the channel between the mobile terminal and the base station for determining the radio sources forming the basis of the signal and the intensities of at least some of the radio sources. Further, the base station in the mobile radio cell adapts the distribution of the radio resources for improving the interference situation at the location of the mobile terminal.

The invention provides a centralized, inbound / outbound communications system that enables communication between one or more entities and one or more users via one or more communication channels. In one embodiment, the multi-channel communications system enables the one or more entities to provide one or more government functions to the one or more users. The multi-channel communications system may include a central data repository; an information module that interacts with the one or more entities and provides data regarding the one or more government functions to the central data repository; a presentation module that enables one or more user interfaces; and one or more communication modules that enable the receipt and transmission of data between the common access point and the one or more users in multiple formats across the one or more communication channels.

A closed loop method and apparatus for controlling the administration of an hypnotic drug to a patient. Electroencephalographic (EEG) signal data is obtained from the patient. At least one measure of the complexity of the EEG signal data is derived from the data. The complexity measure may comprise the entropy of the EEG signal data. The EEG signal data complexity measure is used as the feedback signal in a control loop for an anesthetic delivery unit to control hypnotic drug administration to the patient in a manner that provides the desired hypnotic level in the patient. An EEG signal complexity measure obtained from the cerebral activity of the patient can be advantageously used in conjunction with a measure of patient electromyographic (EMG) activity to improve the response time of hypnotic level determination and of the feedback control of drug administration. A pharmacological transfer function may be used, along with pharmacokinetic and pharmacodynamic models.

The present invention relates to a composition comprising two or more sets of target-specific recombinant polyclonal antibodies, each set being capable of binding to a distinct target, wherein said distinct targets are related to diseases, which may be treated or prevented by the use of antibodies, and wherein said composition is essentially free from immunoglobulin molecules that do not bind to one of said distinct targets. Further the application describes pharmaceutical and diagnostic compositions comprising said composition and use in prevention, treatment and / or amelioration of one or more diseases.

The present invention relates to the field of chemotherapy of diseases such as cell proliferation disorders including cancer. In particular, the present invention relates to the use of hyaluronan (HA) as a protective agent in the treatment of subjects. HA is administered in conjunction with a chemotherapeutic agent to facilitate the prolonged administration of a dose of the chemotherapeutic agent to be administered to a subject. Owing to the protective effects of the HA, the dose of chemotherapeutic agent may be substantially higher than a generally accepted effective dose, which would otherwise be expected to cause unacceptable side effects in the subject.

A medical device for providing guidance to administered cardiopulmonary resuscitation during cardiac arrest in a subject comprising a measuring probe to measure a hemodynamic property of blood flowing through a blood vessel of the subject, an interface element with reference indicia to guide the measuring probe to major blood vessels of the subject experiencing cardiac arrest, and a blood flow monitoring device comprising a data module to collect measured hemodynamic properties of the subject and a guidance module configured to display resuscitation guidance information for manipulating at least one hemodynamic property of the blood.

The present invention concerns methods for the treatment of solid tumors by the inhibition of Lyn associated signal transduction. Preferred in accordance with the invention are inhibitors which comprise sequences derived from specific regions of the Lyn. The present invention further concerns a method for the treatment of cancer by the administration of compounds comprising Lyn-derived peptides.

Pharmaceutical compositions and methods for delivering a polypeptide to the central nervous system of a mammal via intranasal administration are provided. The polypeptide can be a catalytically active protein or an antibody, antibody fragment or antibody fragment fusion protein. The polypeptides are formulated with one or more specific agents.

A system for administering a treatment to individuals infected with a virus such as hepatitis. The system includes an enclosure and at least one gas supply that is used to create an altered atmospheric environment within the enclosure. The patients walk into the enclosure, the super-atmospheric environment is created with the gas, and the patients remain in the super-atmospheric environment for a predefined length of time. The individuals are subsequently returned at a safe rate to normal atmospheric pressure. The treatment can be repeated daily, monthly or annually depending on the needs of the patient. The system includes a control unit that stores and runs at least one treatment program that helps determine treatment variables such as amount of pressure, length of time and the type of gas or gases. It is believed that the present viral treatment may be able to be used in combination with medications and other viral treatments.